Want to see IN:TAKE full AI Analyst Report?
TAKE Stock Chart & Stats
₹20.76
₹0.05(0.24%)
At close: 4:00 PM EDT
₹20.76
₹0.05(0.24%)
Day’s Range― - ―
52-Week Range₹8.83 - ₹49.90
Previous CloseN/A
Volume250.59K
Average Volume (3M)58.94K
Market Cap
₹3.16B
Enterprise Value₹1.67K
Total Cash (Recent Filing)₹186.41M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)29.1
Beta1.27
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding147,934,000
10 Day Avg. Volume129,011
30 Day Avg. Volume58,943
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)18.74
Price to Sales (P/S)10.72
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Zero Reported DebtReported zero total debt in FY2025–FY2026 materially reduces financial leverage and interest burden, giving the company structural flexibility to fund operations or strategic initiatives without immediate refinancing risk. This strengthens balance-sheet resilience over months.
Niche Life-sciences And Supply-chain Software FocusTAKE's product/service mix targets clinical research, regulatory compliance, pharmacovigilance, quality management and supply-chain execution—areas that are mission-critical for customers. Such specialized, compliance-oriented offerings tend to create higher switching costs and recurring demand over time.
Historical Free Cash Flow Strength (FY2021–FY2022)The company delivered strong free cash flow in FY2021–FY2022, demonstrating that its business model can generate operating liquidity under favorable conditions. That historical cash-generation ability suggests potential to recover durable cash flows if revenue and margins stabilize.
Bears Say
Negative Operating Cash Flow In FY2025–FY2026Consecutive annual negative operating cash flow despite reported net income shows weak earnings-to-cash conversion and indicates structural cash generation issues. Persistent negative OCF can constrain reinvestment, force external financing, and undermine the company's ability to sustain operations long term.
Core Profitability Weakness In FY2026Negative gross and operating profits in FY2026 indicate the core business failed to cover direct and operating costs. Positive net income despite this suggests reliance on below-the-line items or one-offs, raising questions about recurring margin sustainability and the quality of reported earnings.
Historical Balance-sheet Instability And Prior Negative EquityPast negative shareholders' equity and prior meaningful debt levels point to historical financial distress and volatility. Even with current zero reported debt, legacy equity impairment and earnings swings signal structural balance-sheet fragility that could resurface under stress.
TAKE Solutions Limited News
TAKE FAQ
What was TAKE Solutions Limited’s price range in the past 12 months?
TAKE Solutions Limited lowest stock price was ₹8.83 and its highest was ₹49.90 in the past 12 months.
What is TAKE Solutions Limited’s market cap?
TAKE Solutions Limited’s market cap is ₹3.16B.
When is TAKE Solutions Limited’s upcoming earnings report date?
TAKE Solutions Limited’s upcoming earnings report date is Aug 11, 2026 which is in 5 days.
How were TAKE Solutions Limited’s earnings last quarter?
TAKE Solutions Limited released its earnings results on May 19, 2026. The company reported ₹0.29 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is TAKE Solutions Limited overvalued?
According to Wall Street analysts TAKE Solutions Limited’s price is currently Overvalued.
Does TAKE Solutions Limited pay dividends?
TAKE Solutions Limited pays a Semiannually dividend of ₹0.4 which represents an annual dividend yield of N/A. See more information on TAKE Solutions Limited dividends here
What is TAKE Solutions Limited’s EPS estimate?
TAKE Solutions Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TAKE Solutions Limited have?
TAKE Solutions Limited has 147,934,000 shares outstanding.
What happened to TAKE Solutions Limited’s price movement after its last earnings report?
TAKE Solutions Limited reported an EPS of ₹0.29 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.961%.
Which hedge fund is a major shareholder of TAKE Solutions Limited?
Currently, no hedge funds are holding shares in IN:TAKE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TAKE Solutions Limited
TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, the company delivers technology-driven and proprietary solutions, alongside consulting and practical services covering clinical trials, regulatory compliance, and patient safety. Its specific offerings in this area include clinical research, development of generic drugs, data analytics, regulatory affairs management, and pharmacovigilance. Beyond this, TAKE Solutions also offers IT infrastructure and support, comprehensive supply chain management, engineering, design, and sourcing services. The company caters to a diverse client base, encompassing both major and smaller innovative biopharmaceutical and medical device firms, as well as generic drug producers. Established in 2000, its main office is located in Chennai, India. TAKE Solutions Limited functions as a subsidiary of TAKE Solutions Pte. Limited.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Syngene International Ltd.
―
OneSource Specialty Pharma Limited
―